3 Mid-Year Mid-Cap Biotech Picks

“All three picks can be volatile but very tradable and should be considered as long term holds with expectations for growth, positive clinical data or M&A,” says the author of today’s article of the three mid-cap biotech stocks he names, all of which are up since the end of May. For these three mid-cap biotech picks – a leading player in the gene editing space, a life sciences company providing temperature controlled logistics solutions, and a genomic diagnostic company – CLICK HERE.